| Description | Lenacapavir (GS-6207) is a potent capsid-targeting inhibitor of HIV replication. Lenacapavir shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. |
| In vitro | Lenacapavir 在外周血单核细胞中对来自不同亚型的23种HIV-1临床分离株表现出平均EC50为50 pM（20-160 pM）。在目标细胞中，Lenacapavir具有23 pM的EC50，在完整周期试验中呈现25 pM的EC50，并且在产生细胞中表现出439 pM的EC50[2]。 |
| Target activity | Anti-HIV:100 pM (EC50), MT-4 cells:100 pM (EC50) |
| Synonyms | GS-6207 |
| molecular weight | 968.28 |
| Molecular formula | C39H32ClF10N7O5S2 |
| CAS | 2189684-44-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 195 mg/mL (201.39 mM), Sonication is recommended. |
| References | 1. John O Link, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Jul 1. 2. Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227. |